Trial · NCT00869323
Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
NCT00869323, Phase 2, Terminated, Masonic Cancer Center, University of Minnesota; results first posted 2017-04-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders. Trials, record NCT00869323. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00869323
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
- NCT number
- NCT00869323
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Lymphoproliferative Disorder
- Interventions
- rituximab, bortezomib
- First posted
- 2009-03-26
- Last updated
- 2017-12-05
- Results first posted
- 2017-04-05
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients With Overall (Complete and Partial) Response Rates | Day 1 to 2 Years Post Treatment | |
| Secondary | Remission Duration Among Patients Who Respond to Treatment | Day 1 to 8 Months Post Treatment | |
| Secondary | Time to Treatment Failure | Day 1 to Time of Disease Progression | |
| Secondary | Relapse-free Survival | at 2 years | |
| Secondary | Overall Survival | at 2 years |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients With Overall (Complete and Partial) Response Rates | Day 1 to 2 Years Post Treatment | participants | NUMBER | |
| SECONDARY | Remission Duration Among Patients Who Respond to Treatment | Day 1 to 8 Months Post Treatment | Both of the participants who responded to treatment were in remission at last contact or death. | months | MEDIAN |
| SECONDARY | Time to Treatment Failure | Day 1 to Time of Disease Progression | Two participants had a complete response at the time they completed the study and were not included in this outcome measure. | months | NUMBER |
| SECONDARY | Relapse-free Survival | at 2 years | participants | NUMBER | |
| SECONDARY | Overall Survival | at 2 years | participants | NUMBER |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Overall (Complete and Partial) Response Rates | Treated Study Participants | 2 | participants | ||
| Remission Duration Among Patients Who Respond to Treatment | Treated Study Participants | 45 | Full Range 22 to 68 | months | |
| Time to Treatment Failure | Treated Study Participants | 1 | months | ||
| Relapse-free Survival | Treated Study Participants | 2 | participants | ||
| Overall Survival | Treated Study Participants | 1 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Induction Therapy | STARTED | Treated Study Participants | 3 | |
| Induction Therapy | COMPLETED | Treated Study Participants | 3 | |
| Induction Therapy | NOT COMPLETED | Treated Study Participants | 0 | |
| Maintenance Therapy | STARTED | Treated Study Participants | 2 | |
| Maintenance Therapy | COMPLETED | Treated Study Participants | 1 | |
| Maintenance Therapy | NOT COMPLETED | Treated Study Participants | 1 |
Source ClinicalTrials.gov
Adverse events36
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Aspartate aminotransferase increased | Investigations | Treated Study Participants | 1 | 3 | |
| other | Alanine aminotransferase increased | Investigations | Treated Study Participants | 1 | 3 | |
| other | Fever | General disorders | Treated Study Participants | 1 | 3 | |
| other | Dehydration | Gastrointestinal disorders | Treated Study Participants | 1 | 3 | |
| other | Anemia | Blood and lymphatic system disorders | Treated Study Participants | 2 | 3 | |
| other | Hypercalcemia | Metabolism and nutrition disorders | Treated Study Participants | 1 | 3 | |
| other | Myoclonus | Musculoskeletal and connective tissue disorders | Treated Study Participants | 1 | 3 | |
| other | Confusion | Nervous system disorders | Treated Study Participants | 1 | 3 | |
| other | Neuropathic pain | Nervous system disorders | Treated Study Participants | 1 | 3 | |
| other | Psychosis | Nervous system disorders | Treated Study Participants | 1 | 3 |
1 to 10 of 36Source ClinicalTrials.gov
See all 36 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treated Study Participants | ||
| Total, other adverse events | Treated Study Participants | 3 | 3 |
| Total, serious adverse events | Treated Study Participants | 2 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00869323
GET https://conductscience.org/api/trials/v1/NCT00869323/events?page=2